According to a recent question from Dr. Jeff Chen, the director of the Cannabis Initiative at UCLA, to the audience at a panel titled, “Impact Investing: Medical Efficacy and Societal Impact of Legal Cannabis,” where Dr. Chen asked the audience to take a guess at the amount of pharmaceutical sales in the United States. “What does that dollar figure look like? Take a wild stab. Somebody shout it out,” he said. The audience obliged, but no one came close.
“The figure, said Dr. Chen, is $500 billion per year, or half of the pharmaceutical industry’s global revenue.”
The entire article from Cannabis Wire can be read below in .pdf format
“The largest speculative investment boom in the history of humankind is going to occur in this space, in this country.”Day 2: Dispatches from the 2019 Institutional Capital and Cannabis Conference
Another interesting panelist is Associate Professor at the University of Houston and Co-Founder/CEO of Canntelligence, Dr. Jokūbas Žiburkus, who was recently announced as MariMed’s Chief Information Officer.
On Thursday, May 9th Dr. Žiburkus will be one of the three experts in a panel discussion at 11:40 AM. The subject of the panel discussion will be Impact Investing: Medical Efficacy and Societal Impact of Legal Cannabis.
MariMed CEO Bob Fireman noted, “Dr. Žiburkus has long been an innovator and thought leader in research and education on beneficial effects of cannabis compounds for a variety of health conditions. As an entrepreneur, he led the development of the hemp-derived health and wellness line of products Florance™, now a premium MariMed Hemp Inc. brand line available in the U.S., Europe, and spreading to other parts of the globe. As the newest member of MariMed’s senior management team, we are pleased that he continues to be at the forefront of innovations for MariMed and the broader industry.”
About MariMed Inc.
MariMed, Inc. is dedicated to improving health and wellness with the highest quality hemp and cannabis products. The company offers a full range of cannabis products, operates state of the art cannabis dispensaries in six states, and has recently announced the formation of a separate division, MariMed Hemp, focused on the development of industrial hemp-derived CBD products. In late 2018 the Company announced a $30MM investment in Kentucky-based GenCanna, a recognized genetic innovator in industrial hemp. Across its branded products, MariMed is in the forefront of precision dosed branded products for the treatment of specific medical symptoms. MariMed currently distributes its branded products in select states and is expanding licensing and distribution to numerous additional markets encompassing thousands of dispensaries.